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INTRODUCTION
Substantial progress has been made in the characterization of recurrent genomic aberrations in acute myelogenous leukemia (AML) and their association with clinical outcomes. In particular, risk groups of AML based on karyotype-based cytogenetics remain important in daily clinical decision-making (1) (2) (3) . Over the last few years, several groups have extended the discovery of multiple recurrently mutated protein-coding genes in AML by reporting the prognostic and therapeutically predictive significance of individual mutations (including NPM1 (4) (5) (6) , FLT3 (7) (8) (9) , CEBPA (10, 11) , DNMT3A (12) (13) (14) , RUNX1 (15) (16) (17) , TET2 (18, 19) , ASXL1 (20, 21) , IDH1 (22, 23) , IDH2 (24, 25) , NRAS/KRAS (26, 27) , and others (31) (32) (33) (34) ) as well as combinations of these mutations (35) (36) (37) (38) in AML patient cohorts. In addition, several groups have published studies demonstrating the correlation of specific SNP array-detected aCNA or the total number of aCNA/cnLOH (genomic complexity) with clinical outcomes (29, (39) (40) (41) (42) (43) . Importantly, however, the relative influence on clinical AML outcomes of different types of genomic alterations, including gene mutations, structural genomic changes or aCNA/cnLOH, remains unclear as lesion types rarely occur in isolation. While a few integrated analyses of the patterns of co-occurrence of various genomic alterations have been published (44) , these studies have not extended findings to the study of chemoresistance and survival.
The majority of studies assessing the prognostic value of mutated genes in AML have been restricted to AML with normal karyotype (NK-AML) since this category is clinically heterogeneous, lacks a prognostic structural genomic marker and because some mutated genes are enriched in NK-AML. The published cohorts studied often are selected based on clinically-derived classifications of AML subgroups, including secondary AML (sAML) that arises in the setting of an antecedent myeloid neoplasm, and de novo AML (dnAML) that presents without a history of either previous therapy or a pre-existing myeloid neoplasm. Since many of these studies are based on cohorts of patients enrolled on therapeutic trials, they are subject to selection based on age and other inclusion and exclusion criteria, which adds further restrictions on the population analyzed.
To further refine basic biological knowledge of patterns of occurrence of genomic lesion types in AML and of the effects of various genomic aberration types on AML outcome, we profiled a consecutively enrolled prospective AML cohort for aCNA/cnLOH using SNP 6.0 array profiling and determined the mutation status of 13 recurrently mutated genes using Sanger sequencing. This approach has allowed us to integrate multiple genomic features across all major clinical subgroups of non-M3 AML and across the full age range of adult patients. Here we identify genomic traits that associate with clinical AML subtypes, gene mutations that associate with genomic complexity or stability, and genomic traits that associate with sensitivity or resistance to standard induction therapy and ultimately survival.
phycoerythrin-conjugated anti-CD13, and allophycocyanin-conjugated anti-CD45 (all antibodies: eBioscience). Live cells (PI-negative) were gated for blasts by identifying cells with intermediate-intensity staining for CD45 and low-to moderate-intensity side scatter.
CD33 and CD13 were used to further discriminate blasts versus erythroid and mature myeloid lineage cells. This strategy resulted in a ≥90% pure blast population(45) that was confirmed with morphological inspection of cytospins. DNA was extracted as previously described (46) .
Exon resequencing of 13 recurrently mutated genes in AML
All coding exons and adjacent intronic sequences of CEBPA, ASXL1, TET2, DNMT3A, RUNX1, and BCORL1 along with exon 12 of NPM1, exons 13-15 and 20 of FLT3, exons 2-10 of TP53, exons 2-3 of KRAS and NRAS, exon 2 of IDH1, and exon 4 of IDH2 with adjacent intronic sequences were resequenced using PCR and sequencing primers designed with the primer3 tool; sequence information was generated as previously described (45) . All mutations were confirmed using unamplified tumor DNA and paired patient buccal DNA as templates.
Array Data Analysis
Affymetrix CEL files for each blast and buccal sample underwent initial quality control screening with the Genotyping Console program afterwhich Affymetrix "Birdseed" algorithm generated SNP call files with call rates for the entire sample group between 93.64% and 99.45%, with a mean call rate of 98.17%; none gave out-of-bounds results.
Genomic copy number heatmaps were generated as previously described (45) . Two independent observers visually inspected parallel heatmap copy number images of AML blast and paired normal DNA samples generated through dChip. Only those copy number changes detected in blast DNA but not in paired normal DNA were called somatic, and lesions had to be ≥30 SNP positions in length to be scored positive. All visually determined aCNA were corroborated with an algorithmic lesion calling method as previously described (47) . LOH analysis was performed using LOH tool v2 as previously described (29) .
All resulting aCNA/cnLOH are listed in Supplementary Table 3 and SNP 6.0 array data files for all 156 patient samples analyzed were deposited in the GEO public database (accession number GSE61323).
TCGA Data Analysis
The recently published AML cohort of The Cancer Genome Atlas (TCGA) provided additional clinically-annotated gene mutation and SNP-A patient data (44) . To facilitate a meaningful comparison of aCNA/cnLOH from TCGA with the Michigan cohort, SNP 6.0 Affymetrix CEL files from paired normal and tumor TCGA AML specimens were downloaded from dbGaP after obtaining data access approval (dbGaP approval #29753-3). These files were analyzed with the identical informatics pre-processing pipeline and visual and algorithmic lesion calling methods used for the Michigan SNP 6.0 arrays above.
Of the 200 published matched pairs, twenty were excluded due to a diagnosis of APL (AML-M3), two for out-of-bounds results (TCGA-2855 and -2883), two for failure to pass the "Birdseed" algorithm (TCGA-2848 and -2981), and six for high visual and algorithmic background noise that precluded accurate lesion calling (TCGA-2802, -2833, -2843, -2847, -2876 and -2891). This resulted in 170 matched pairs with a complete catalog of aCNA/cnLOH, which is included in Supplementary Table 3 . Gene mutation status for the thirteen genes of interest in this study and clinical characteristics including survival data based on the 5/13/2013 update were obtained from published supplementary data (44 Michigan cohort include the use of whole exome or genome sequencing followed by nonSanger based confirmation of gene mutation status and the use of tumor samples that were not enriched for leukemic cells.
Statistical Methods
Overall survival was defined as time (in months) between AML diagnosis and the patient's death. For patients still alive the censoring date was September 1, 2013.
Univariate and bivariate analyses were based on Kaplan-Meier estimates of survivor functions. Median survival times were estimated directly from the survivor function estimates. Significance levels for group-wise comparisons in the univariate analyses assess whether the hazard ratio between groups differs from 1 in a Cox proportional hazards model.
For bivariate analyses, Cox models were fit to sub-samples defined by the levels of one of the two factors being analyzed. The reported p-value assesses whether the univariate hazard ratio for the other factor differs from 1 within the sub-sample. Multivariate analyses were based on Cox proportional hazards models with additive effects for the factors as reported in the results. The reported significance levels assess whether the hazard for a given factor differs from 1 when the other factors in the model are held fixed.
Comparison of clinical features of the various groups studied was performed using two-sided Chi-squared, Mann-Whitney, and Kruskal-Wallis tests. Pairwise associations between gene mutations, recurrent aCNA/cnLOH, etiological AML subtypes, and type of response to induction chemotherapy were calculated using a two-sided Fisher's exact test corrected for multiple hypotheses testing with the Benjamini-Hochberg FDR algorithm and denoted using q-values. The standard error of the mean (SEM) was calculated for the mean number of aCNA/cnLOH associated with each mutated gene. 
RESULTS

Patient Characteristics
Characteristics of the 156 prospectively enrolled, previously untreated, non-M3 FAB subtype AML patients (referred to hereafter as the "MI-All-AML" group) in this study are summarized in Supplementary Tables 1 and 2 . Of the 156 patients, 114 underwent SNP-A analysis and limited gene sequencing in a previously published study (29) . Sixty-six percent, 22%, and 12% of cases were dnAML, sAML, or tAML, respectively and 35% (54/156) of cases had normal cytogenetics. Within the dnAML group 17% had a recurrent genomic abnormality, 19% had myelodysplasia-related changes without a history of an antecedent myeloid neoplasm, and 64% were diagnosed as AML-not-otherwise-specified. Forty-two percent (43/103) of dnAML cases had normal cytogenetics. Regarding therapy, 93%, 66%, and 78% of dnAML, sAML, and tAML cases, respectively, received high-intensity induction chemotherapy, and 30% (47/156) underwent allogeneic stem cell transplantation while in complete remission, 45% (21/47) of whom were alive >3 years after diagnosis. Seventy-six percent (119/156) of patients had died at the time of data analysis, and median follow-up for surviving patients was 57.4 months.
Clinical characteristics of the AML TCGA cohort are published elsewhere (44) . Of note, the TCGA data set comprises only dnAML cases and is compared in this study with the dnAML subgroup of Michigan cases (hereafter referred to as the "TCGA-dnAML" and "MIdnAML" groups, respectively). The clinical features of the TCGA-dnAML and MI-dnAML groups are well matched with the exception of the fractions receiving high-intensity treatment (79% vs 93%, respectively; p<0.01). The comparison of these two groups is summarized in 
Supplementary
Mutational spectrum of thirteen genes across clinical AML subsets
Mutation frequency of 13 recurrently mutated genes is summarized in Figure 1A .
Eighty percent (125/156) of cases had a mutation in at least one of these genes. IDH2 (19% vs. 3%), NPM1 (24% vs. 3%), and FLT3 (21% vs. 11%) mutations were enriched in dnAML compared with sAML (p≤0.05 for all), while IDH1 (17% vs. 8%), ASXL1 (26% vs. 13%), and TP53 (26% vs. 8%) mutations were overrepresented in sAML compared with dnAML (p≤0.05 for all). For tAML, 50% (9/18) of cases harbored mutant TP53 ( Figure 1B) . ASXL1 occurred more frequently in patients ≥60 years old (p=0.05) due to the increased proportion of sAML in that population; however, comparing age ≥60 to age <60 in the dnAML group alone showed enrichment of RUNX1 and TET2 in older patients (both 22% vs. 7%, respectively; p<0.05), while the remaining eleven genes showed no significant difference in mutation frequency. Co-occurrence analysis of mutations in all AML cases demonstrated mutual exclusivity of TP53 and RUNX1, NPM1 and RUNX1, and IDH1 and IDH2 ( Figure   1A ). A detailed catalog of gene mutations for each case is included in Supplementary   Table 4 . Mutation frequency in these subgroups was consistent with published data with the exception of ASXL1 in dnAML (13% vs 3%) (36, 44) and TP53 in tAML (50% vs 18-21%) (48, 49) .
Topography of aCNA and cnLOH
A total of 455 copy number losses, 106 copy number gains, and 38 instances of cnLOH were identified, with 20% <1 Mb and 47% <5 Mb (Supplementary Table 3 ).
aCNA/cnLOH were common in the MI-All-AML group with 62% (97/156) of cases harboring Examining the association of gene mutations with each MADR revealed significant association between KRAS and trisomy 8 (q=0.04), BCORL1 and trisomy 21 (q=0.01), and TP53 with all recurrent aCNA/cnLOH except for 6p-, 11q-, 13q+, 21+, and 21q-.
Associations of gene mutations with SNP-A-based genomic complexity
Comparison of SNP-A-based genomic lesion loads in the MI-All-AML, MI-dnAML or a combined dnAML (MI-dnAML and TCGA-dnAML) group further subdivided by individual or CEBPA mutations; iii) >50% of cases with mutations in BCORL1, KRAS, RUNX1, NRAS, TET2, DNMT3A, ASXL1 or IDH2 harbored ≥1 aCNA/cnLOH (Figure 2A) , and, iv) AML cases without mutations in the 13 genes analyzed here were quite complex. In the MI-All-AML group, TP53 mutations were strongly associated with the presence of aCNA/cnLOH and NPM1 mutations with their absence (q<0.01 for both), while in the pooled dnAML group TP53 and RUNX1 mutations were strongly associated with the presence of aCNA/cnLOH and NPM1 and FLT3 mutations with their absence (q<0.01 for all).
A parallel analysis was performed on TP53 wildtype cases; in this group, a subset of cases within each mutation-carrying subgroup still carried high lesion loads ( Figure 2B ) and substantial differences existed in the fraction of cases that carried no lesions. Specifically, in the pooled dnAML group, RUNX1 mutations remained strongly associated with the presence of aCNA/cnLOH and NPM1 and FLT3 mutations remained strongly associated with their absence (q<0.01 for all). In both the TP53 any and TP53 wildtype analyses, the majority of cases with BCORL1 and KRAS mutations also contained aCNA/cnLOH and almost all cases 
Association of gene mutations, aCNA/cnLOH and karyotype with refractory AML
Within the total cohort (MI-All-AML), 132 patients received full-intensity induction chemotherapy; of these, 13 patients died during cycle one of induction chemotherapy and one declined further treatment and these patients were excluded from subsequent analysis.
Of the remaining 118 patients, 65% (76/118) achieved a morphological complete remission (CR) after one cycle of therapy (referred to hereafter as the "sensitive" group), 15% (18/118) achieved a CR after two cycles of therapy (the "intermediate" group), and 20% (24/118) failed to achieve a CR after at least two cycles of therapy (the "refractory" group). Univariate Figure 3B . 
Age, cytogenetics and gene mutations and survival in the AML cohorts studied
In the MI-All-AML group, median overall survival (OS) for age ≥60 (6. In the MI-All-AML cohort, a statistically significant increase in median survival was observed for NPM1 mutated (26.9 months) versus NPM1 wildtype (9.0 months) cases mutated (2.9 months) versus TP53 wildtype (13.4 months) cases (p<0.001). The remaining eleven genes showed no significant difference in median survival.
In the MI-dnAML subgroup alone (N=103), a significant decrease in median survival was seen with TET2 mutated (6.8 months) versus TET2 wildtype (17.8 months) cases (p=0.03) and TP53 mutated (2.9 months) versus TP53 wildtype (18.0 months) cases (p<0.01). A trend toward decreased median survival was noted with RUNX1 mutated (11.5 months) versus RUNX1 wildtype (18.1 months) cases (p=0.06). The remaining ten genes showed no significant difference in median survival.
In the TCGA-dnAML group (N=170), a significant decrease in survival was again seen in TP53 mutated (7.0 months) versus TP53 wildtype (16.4 months) cases (p<0.01), RUNX1 mutated (12.5 months) and RUNX1 wildtype (14.6 months) cases (p=0.04), and DNMT3A mutated (9.9 months) versus DNMT3A wildtype (15. Table 5 ).
An independent adverse effect of aCNA/cnLOH count ≥3 in TP53 wildtype or mutant cases was not detected. Analysis of the clinical features of the TP53 mutant and wildtype subgroups within the TCGA and MI-AML groups shows that while the TP53 mutant groups are well matched (median age 67 vs 68 and BMT as consolidation in 27% vs 25%, respectively), the TCGA TP53 wildtype subgroup with aCNA/cnLOH count ≥3 harbored substantial differences compared with MI-AML (median age 60 vs 69 and BMT as consolidation in 67% vs 18%
[p=0.03]), which may explain the lack of observed effect of elevated genomic complexity on outcomes in the TCGA TP53 wildtype subgroup.
Research. methodology and lower rates of use of intensive therapies limit to some extent a direct comparison of genomic findings and may account for some of the differences observed.
Given that genomic complexity resulting from genomic instability as measured by SNP-A-based aCNA/cnLOH counts is strongly associated with poor survival and chemoresistance in AML and given that the effect of the presence of such genomic instability supersedes that of mutations in all commonly mutated genes in AML evaluated with the exception of TP53 and possibly TET2, multiple relevant questions arise. Is genomic complexity (and the underlying pathogenic mechanisms that lead to it) one of the defining characteristics upon which clinical and biological AML subgroups should be defined? Are recurrent AML associated gene mutations other than TP53 more associated with AML initiation or clonal outgrowth rather than with chemotherapy resistance? If so, are the observed relationships of these mutations with AML prognosis in part indirect and due to cooccurrence or conversely the lack of association with either TP53 mutations or genomic instability?
In summary, our data demonstrate that RUNX1 mutations, ASXL1 mutations, SNP 6.0 array-based deletions/cnLOH of 5q, 7q, 12p, and 16q and elevated SNP 6.0 array-based genomic complexity significantly predict partial or complete resistance to induction chemotherapy even in the absence of a co-occurring TP53 mutation. Furthermore, highly adverse prognostic information in AML can be derived from determinations of patient's age, karyotype, TP53 mutation status and/or SNP 6.0 array-based genomic complexity, which should be measured routinely for all patients with AML at diagnosis. Table 1 Research.
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